Using Animal Pharmacokinetics to Convert NOAEL to Human Exposure

Why Connect a NOAEL Dose to Exposure?

A no-observed-adverse-effect level (NOAEL) is a dose from a particular animal study, expressed in units such as mg/kg/day. It is not itself a plasma concentration or an exposure. The same dose can produce different exposures in different species because clearance, bioavailability, and other pharmacokinetic properties differ. For first-in-human planning, this creates two related but distinct questions: what human dose corresponds to the animal NOAEL by a dose-conversion method, and what systemic exposure is expected at a proposed human dose?

Animal pharmacokinetic data help answer the second question and put the NOAEL in exposure context. If the animal exposure at the NOAEL is known, it can be compared with the exposure predicted at the proposed human dose. This comparison is an evidence chain, not a guarantee of safety: it depends on the quality of the animal toxicology and pharmacokinetic data, the human clearance prediction, and assumptions about dose proportionality and route.

From Dose and Clearance to AUC

For a drug with linear pharmacokinetics, systemic exposure over a complete dosing interval is related to the systemically available dose and clearance. Let \(D\) be the dose per interval, \(F\) the fraction of the dose reaching systemic circulation, \(CL\) systemic clearance, and \(\tau\) the dosing interval. At steady state, the relationship is:

For a single dose with exposure followed until concentrations have effectively returned to baseline, the corresponding relationship is \(AUC_{\infty}=FD/CL\). The equation follows from mass balance: under linear pharmacokinetics, the amount eliminated over the full interval equals \(CL\) multiplied by AUC. At steady state, the amount eliminated during an interval equals the systemically available dose, \(FD\). Equating these gives \(CL \times AUC_{\tau}=FD\), and division by \(CL\) gives the stated result.

The relationship assumes that clearance is constant over the relevant concentration range, the dose and interval are defined correctly, and the AUC covers the same interval or exposure period for the species being compared. If AUC is measured directly in an animal toxicokinetic study, that observed value is usually a more direct exposure anchor than an estimate calculated from dose and clearance. If clearance is used to calculate AUC, its units and basis must match the dose: for example, an animal dose in mg/kg requires clearance in L/h/kg, while a total dose in mg requires clearance in L/h.

The fraction \(F\) must also be handled consistently. For a route with complete systemic availability, \(F=1\). If \(F\) is known to be below one, it belongs in the calculation; if it is unknown, the calculation must state the assumption or use an appropriate apparent clearance parameterization. Route and bioavailability can materially affect the comparison, so they should not be silently assumed to match.

Keeping Dose Conversion Separate from Exposure Prediction

A human equivalent dose (HED) derived from an animal dose is a dose conversion, often based on body-surface-area scaling. For a specified animal species, the conventional conversion is \(HED =\) animal dose \(\times K_m\) for that species \(/\ K_m\) for humans, with both doses expressed per kilogram. This conversion does not establish that the animal and human exposures are equal. Clearance and bioavailability can differ even when doses have been converted to HED.

To estimate human exposure at a proposed starting dose, use the proposed dose and predicted human clearance in the exposure relationship. Compare that estimate with the animal NOAEL exposure anchor only after confirming that the measures represent comparable analytes, routes, and exposure periods. An exposure margin can be defined as animal NOAEL exposure divided by predicted human exposure. A larger ratio means the animal exposure anchor is numerically higher than the predicted human exposure; it does not, by itself, quantify the probability of an adverse event or prove that the proposed dose is safe.

Assumptions, Diagnostics, and Failure Modes

Before interpreting an exposure comparison, check whether its inputs support the calculation. A measured animal AUC should come from the relevant NOAEL group, dose, route, and dosing schedule. If it is estimated from clearance, confirm that clearance is appropriate for that species and dose range. Human clearance should be a prediction with an explicit basis and units, rather than an unqualified point value.

• Check dose proportionality. If dose-normalized AUC changes across doses, clearance or bioavailability may vary with dose. A linear extrapolation from one dose may then mispredict exposure at another.
• Check sampling and interval. AUC derived from sparse sampling or incomplete coverage may not represent the full dosing interval. Comparisons between steady-state interval AUC and single-dose AUC also require care.
• Check the analyte. Parent-drug exposure, active-metabolite exposure, total concentration, and unbound concentration are not interchangeable. The animal and human measures must be defined consistently.
• Check species relevance. Species differences in metabolism or transport can undermine the assumption that exposure to the measured analyte has comparable meaning across species.
• Check the exposure metric. Clearance and dose can support an AUC estimate under the stated conditions, but they do not determine the concentration-time profile or peak concentration on their own.

When a human clearance prediction is uncertain, a single exposure estimate can imply more precision than the evidence warrants. A useful diagnostic is to calculate exposure across a plausible clearance range and report how the comparison changes. Likewise, if animal AUC is available from toxicokinetic sampling, compare that observation with the dose-clearance estimate as a consistency check. A substantial disagreement is a signal to investigate dose proportionality, clearance estimation, bioavailability assumptions, or data quality before relying on the margin.

How This Comparison Fits into Dose Selection

The dose-based approach and the exposure-based approach are complementary. HED conversion provides a scaled dose reference, while animal pharmacokinetics connects the NOAEL dose to an exposure anchor. Predicted human pharmacokinetics then estimates what exposure a proposed dose may produce. Direct exposure matching can be useful when exposure measurements are reliable, but it inherits uncertainty in animal data and human clearance. Neither method should be treated as an automatic replacement for the other.

A common mistake is to say, “The proposed human dose is one-tenth of the HED, so human exposure must be one-tenth of the animal NOAEL exposure.” That conclusion assumes equal exposure per unit dose across species, which generally does not follow from HED scaling. The correction is to calculate or measure the animal NOAEL exposure, separately predict human exposure at the proposed dose, and then compare like with like. Another mistake is to interpret an exposure margin as a guaranteed safety margin. It is only a numerical comparison of specified exposures; toxicological relevance and uncertainty still require scientific judgment.